In recurrent GBM settings, one trial testing Pembrolizumab (NCT02658279) is underway using patient selection according to hypermutant status; tumors as either having a mutation count of >30 using the MSK-IMPACT panel, mutation in one or more MMR genes (MLH1, MSH2, MSH6, PMS2, POLE or POLD), or high MSI. This evidence concerns the gene POLE and glioblastoma.